Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05799378 · ClinicalTrials.gov registry record · Phase 3
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
A Phase 3 study of Systemic Lupus Erythematosus, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 10
- Study locations
NCT05799378 is a Phase 3 study of Systemic Lupus Erythematosus that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 330 participants, below the 377-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (12% lower). The trial reports 10 study locations across 5 states.
The verdict
NCT05799378, a Phase 3 study of Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 10
- Study locations
Study Summary
Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a track record of safety with regard to infection compared to traditional immunosuppressive agents, the risk of HCQ retinal toxicity escalates with continued use. Evaluation using sensitive standard of care approaches suggests nearly a third of patients accrue retinal damage. Data are needed to accurately weigh the balance between accumulating ocular exposure of HCQ versus the risk of disease flare in a population that may have more inactive disease than younger patients. The purpose of this trial is to address the safety of withdrawal of HCQ in SLE patients =60 years old. The central hypothesis is that HCQ can be safely discontinued in stable/quiescent patients assessed by validated disease activity and flare instruments in the context of serologic, cytokine and transcriptomic profiling. Patients will be randomized to either the placebo or active arm and followed every 2 months for one year to assess disease activity and flares.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Hydroxychloroquine
Study Locations (10)
New York
- VA NY Harbor Healthcare System - New York
- NYC Health + Hospitals/Bellevue - New York
- NYU Langone Health - New York
- Hospital for Special Surgery - New York
- Columbia University Irving Medical Center/New York Presbyterian - New York
- Montefiore Medical Center/Albert Einstein College of Medicine - The Bronx
California
- University of California, Los Angeles - Los Angeles
New Jersey
- Hackensack Meridian Health - Hackensack
Oklahoma
- Oklahoma Medical Research Foundation - Oklahoma City
Pennsylvania
- Penn State MS Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2024-06-27 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05799378
The ClinicalTrials.gov registry entry for NCT05799378 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (12% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05799378 reports 10 study locations spanning 5 distinct geographic areas - top geographies include New York, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05799378 about?
NCT05799378 is a clinical study titled "Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease". Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a track record of safety with regard to infection compared to traditional immunosuppressive agents, t...
What is the current status of trial NCT05799378?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2024-06-27. Estimated completion is 2029-06-30.
What conditions does trial NCT05799378 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT05799378?
The interventions under investigation include: Placebo (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT05799378?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05799378 being conducted?
This trial has 10 study locations across California, New Jersey, New York, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
RECRUITING · Phase 3
-
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.